Business
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales – NEW HAVEN, Conn., May 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, and Pfizer Inc. (NYSE: PFE) have entered into a license agreement with Rigel Pharmaceuticals, Inc., a commercial s
About this update from Arvinas, Inc.
[{"type":"image","alt":"Arvinas Inc.","displaySize":"","headline":null,"caption":"Arvinas Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":109,"url":"https://media.zenfs.com/en/globenewswire.com/18463b2f9b1fb1b232297c330cb1779a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jLkqP7i6zY4aZeuWLt1_Tg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1Mw--/https://media.zenfs.com/en/globenewswire.com/18463b2f9b1fb1b232297c330cb1779a","width":300,"height":109},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/jLkqP7i6zY4aZeuWLt1_Tg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1Mw--/https://media.zenfs.com/en/globenewswire.com/18463b2f9b1fb1b232297c330cb1779a","width":300,"height":109}},"lazy":false},{"type":"text","content":"– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales –","length":211,"tagName":"p"},{"type":"text","content":"NEW HAVEN, Conn., May 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, and Pfizer Inc. (NYSE: PFE) have entered into a license agreement with Rigel Pharmaceuticals, Inc., a commercial stage biotechnology company focused on hematologic disorders and cancer, for the exclusive global development, manufacturing, and commercialization rights for VEPPANU™ (vepdegestrant). VEPPANU is the first U.S. Food and Drug Administration (FDA) approved PROteolysis TArgeting Chimera (PROTAC), a type of heterobifunctional protein degrader.","length":628,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Arvinas and Pfizer will receive an upfront payment of $70 million and an additional $15 million upon successful completion of select development and manufacturing transition activities, to be distributed evenly between Arvinas and Pfizer. Arvinas and Pfizer will also be eligible to receive up to $320 million in future development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales in the mid-teens to mid-20s, distributed evenly between Arvinas and Pfizer.","length":530,"tagName":"p"},{"type":"text","content":"Rigel will be responsible for the launch and commercialization of VEPPANU in the U.S. and will own g...